Engflag

Atorval

Quick links to important sections

Atorval

Atorval_EN

Method of action: Hypocholesterolemic, Inhibiting Hmg-Coa Reductase, Lipid Modifying Agents, Lipid-Lowering

Treatment option: Hyperlipidemia, Hypercholesterolemia, Prevention Of Cardiovascular Disease, Familial Hypercholesterolemia

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Atorval

Property Description
Active ingredient Atorvastatin (INN)
Form Film-coated tablet
Pharmacological class Statin (HMG-CoA Reductase Inhibitor)
Common use Reduction of high blood cholesterol
Origin Synthetic compound

What Type of Medicine is Atorval?

Atorval is a prescription-only medicine whose active component is the substance atorvastatin. It belongs to the drug class known as statins, formally classified as an HMG-CoA reductase inhibitor, establishing it as an antihyperlipidemic agent. This classification is clinically recognized for identifying agents that modify the body's internal cholesterol production.

Atorvastatin is a synthetic lipid-lowering agent, meaning the compound is chemically manufactured rather than derived from a natural source. The Atorval brand is typically presented as a film-coated tablet designed for oral administration, offering an established option for patients managing high cholesterol.

The Role of Atorval in Lipid Management

Atorval's general therapeutic purpose is the management of elevated blood fat levels, including hypercholesterolemia and various forms of dyslipidemia. Atorvastatin's primary action is centered on significantly reducing levels of low-density lipoprotein cholesterol (LDL-C), often termed "bad" cholesterol. Research confirms that statins are a cornerstone treatment option for lipid disorders.

This means the medicine acts as a preventative measure to help guard against the long-term progression of fatty plaque buildup in the arteries. A typical use scenario involves long-term maintenance therapy for adults who have not achieved their lipid goals through diet and lifestyle adjustments alone.

Composition and Physical Form of Atorval

Atorval is prepared as a single-ingredient product delivered in the form of a film-coated tablet. The formulation contains the active substance, atorvastatin (stabilized as the calcium salt), alongside necessary solid pharmaceutical excipients. These are inactive components included to ensure the product's stability and consistent delivery of the active compound once the medicine is ingested.

Regulatory References

  1. Statins in Lipid-Lowering Drug Therapy (StatPearls)

What side effects are possible with Atorval?

Possible Side Effects and Safety Information

The official safety profile for atorvastatin, the active component in Atorval, details potential adverse reactions classified by incidence rate and the body system affected. This regulatory framework distinguishes between frequently observed reactions and rare, serious events.

Frequency-Classified Adverse Reactions

Adverse reactions are classified in regulatory documents according to incidence:

  • Common (occurring in 1 in 100 to 1 in 10 users): May include nasopharyngitis, headache, myalgia (muscle pain), arthralgia (joint pain), and gastrointestinal effects like diarrhoea or flatulence.
  • Uncommon (occurring in 1 in 1,000 to 1 in 100 users): Examples include insomnia, amnesia, dizziness, and urticaria.
  • Rare (occurring in less than 1 in 1,000 users): Includes serious reactions such as rhabdomyolysis (severe muscle breakdown) and hepatic failure (severe liver impairment). Myositis (muscle inflammation) and peripheral neuropathy are also listed.

System-Organ-Class Groupings

The documented effects are grouped by system, including Musculoskeletal and Connective Tissue Disorders (e.g., muscle and joint issues), Gastrointestinal Disorders, Nervous System Disorders, and Hepatobiliary Disorders (liver-related effects).

Population-Specific Safety Constraints

Regulatory documentation establishes constraints for certain populations:

  • Pregnancy and Lactation: Atorval is contraindicated during pregnancy due to the risk of fetal harm, and breastfeeding is not recommended.
  • Active Liver Disease: Use is contraindicated in patients with active liver disease or unexplained persistent elevations of liver enzymes.
  • Dose-Related Risk: An increased risk of hemorrhagic stroke was noted in a post-hoc analysis for the 80 mg dose in certain patients with a history of stroke.

Time-Related Safety Observations

Some documented safety signals are noted for their time-related pattern. For instance, reports of cognitive impairment (such as confusion or memory loss) have been generally reversible upon discontinuation of the medicine.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Atorval overdose is defined by the risk of severe toxicity to the skeletal muscle and hepatic systems. Documented manifestations requiring immediate attention include unexplained muscle pain, tenderness, or weakness, especially when accompanied by dark-colored urine or other signs of muscle breakdown (rhabdomyolysis). Clinical symptoms of serious hepatic injury, such as jaundice (yellowing of the skin or eyes), are also documented overdose presentations. Laboratory findings associated with toxicity include markedly elevated Creatine Kinase (CK) levels and increased serum transaminases.

Required Emergency Action

Immediate medical attention is officially required if any systemic, life-threatening symptoms are observed. Emergency services and the Poison Control Helpline must be contacted immediately if the affected person has collapsed, experienced a seizure, is having trouble breathing, or cannot be awakened.

Management of overdose is primarily symptomatic and supportive, as regulatory documents state that no specific antidote is known. The medication must be promptly discontinued if suspected rhabdomyolysis or serious hepatic injury is diagnosed. Population-specific notes list advanced age (over 65), renal impairment, and uncontrolled hypothyroidism as predisposing factors for severe outcomes.

Therapeutic Uses of Atorval

What Atorval Treats: Main Uses and Benefits

This medication is commonly used across domains where additional symptomatic support is needed. It helps manage the long-term risk associated with “Bad” cholesterol (LDL-C) and triglycerides in the blood. This medication is commonly used across conditions presenting with acute episodes and is applied in scenarios where additional management of discomfort is required, such as in patients with existing heart disease or diabetes.

This therapy contributes to maintaining functional stability and supports the patient's efforts in addressing systemic imbalance.

This medicine is considered relevant for easing the long-term risk of cardiovascular episodes that involve acute or disruptive symptoms. By addressing symptoms related to systemic imbalance, this medication may assist with managing the underlying vascular condition and supports general well-being during symptomatic phases.

Quick Fact: Relief for Silent, Underlying Risk This medicine is relevant for preventative needs, addressing conditions associated with acute or disruptive episodes that typically produce no noticeable discomfort themselves, with the goal of supporting patients during episodes of heightened discomfort.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Scope for Atorval

The eligibility profile for Atorval (atorvastatin) is defined by official regulatory documentation, which sets mandatory exclusions and age-dependent limitations for its use.

Classification Population Group Details from Regulatory Labeling
Contraindicated Active Liver Disease Must not be used in patients with active liver disease or unexplained, persistent elevations of serum transaminases (liver enzymes) [FDA/EMA].
Contraindicated Pregnancy & Lactation Use is contraindicated in women who are pregnant or are breastfeeding [FDA/EMA]. Women of child-bearing potential must use effective contraception.
Permitted Adults Use is allowed for adults (18 years and older) for labeled hyperlipidemia and cardiovascular indications.
Permitted/Restricted Pediatric Use is permitted for patients 10 years and older only for specific conditions such as Heterozygous Familial Hypercholesterolemia.
Not Recommended Children under 10 Use is generally not recommended or not established in children younger than 10 years of age.

Regulatory documents also note that renal impairment is a risk factor for myopathy, and patients with pre-disposing factors for rhabdomyolysis, such as uncontrolled hypothyroidism or advanced age (over 65), require special consideration and assessment.

What should I know about interactions with other medicines?

This section outlines the officially documented interaction profile of Atorval (atorvastatin), based strictly on regulatory sources like FDA and EMA prescribing information.

Interaction Scope

Classification Interacting Agents (Examples) Official Regulatory Statement
Contraindicated Glecaprevir/Pibrentasvir Co-administration is formally prohibited due to severe exposure increase.
Increased Exposure Potent CYP3A4 Inhibitors (Clarithromycin, Itraconazole, Cyclosporine), OATP/BCRP Inhibitors Increase Atorvastatin plasma concentrations (AUC), heightening the risk of muscle-related effects.
Additive Risk Fibric Acid Derivatives (Gemfibrozil), Lipid-modifying doses of Niacin ( ge 1 g/day), Colchicine Increase the additive risk of myopathy and rhabdomyolysis.
Timing-Sensitive Rifampin Requires simultaneous co-administration; delayed administration significantly reduces Atorvastatin concentration.

Food and Population Notes

  • Food/Substance Restriction: Consumption of large quantities of Grapefruit Juice (ge 1.2 liters daily) is not recommended. Caution is advised for patients who consume substantial quantities of alcohol.
  • Affected Substances: Atorval co-administration increases the plasma levels of Oral Contraceptives (Norethindrone and Ethinyl Estradiol) and Digoxin.
  • Population Note: Official labeling notes that Atorvastatin plasma concentrations are markedly increased in patients with Hepatic Impairment.

Connection to the Overall Interaction Profile

The regulatory profile highlights that Atorval's interaction structure is primarily defined by its dependence on CYP3A4 enzyme and drug transport proteins. Interference with these pathways, or the presence of agents with additive toxicity, establishes specific constraints on co-administration, ranging from monitoring requirements to absolute prohibition, as documented in official government labeling.

Mechanism of Action

How Atorval Works

HMG-CoA Reductase Inhibition

Atorval acts as a selective and competitive inhibitor of HMG-CoA reductase, the enzyme responsible for catalyzing the rate-limiting step in cholesterol biosynthesis, primarily within the liver. By blocking the conversion of HMG-CoA to mevalonate, Atorval decreases the total amount of cholesterol synthesized by the hepatocytes.

LDL Receptor Upregulation and Clearance

This reduction in intracellular hepatic cholesterol concentration triggers a compensatory feedback mechanism. This physiological process results in the upregulation of low-density lipoprotein (LDL) receptors on the surface of liver cells. The increased number of receptors enhances their capacity to bind and facilitate the catabolism of circulating LDL-C (low-density lipoprotein cholesterol) from the plasma. The resulting effect is a modulation that lowers circulating plasma concentrations of LDL-C.

Dosage and Administration Information

How to Use Atorval

Official instructions for using atorvastatin (Atorval) structure its administration around a standardized, non-instructional protocol, defining the route, schedule, and dose parameters as specified in the product documentation.

Parameter Official Instruction
Route of Administration Oral (by mouth), typically as a film-coated tablet in strengths of 10 mg, 20 mg, 40 mg, or 80 mg.
Dosing Schedule (Adults) The approved dose range is 10 mg to 80 mg once daily. Therapy is commonly initiated at 10 mg or 20 mg, with the maximum recommended daily intake being 80 mg.
Timing & Meals The tablet may be ingested with or without food and can be taken at any time of the day.
Frequency Pattern Administered as a single dose once daily (qDay).

Protocol for Dose Adjustment and Specific Populations

Dosage recommendations are established for long-term use. No general dose adjustment is required for patients with existing renal impairment or based on age alone for older adults. For pediatric patients (aged 10 years and older) with heterozygous familial hypercholesterolemia, the starting dose is 10 mg once daily, with the maximum dose for this indication being 20 mg daily.

The protocol for dose modification requires that any adjustment to the daily dose be assessed and implemented at intervals of 4 weeks or more after the initiation of treatment or a previous titration. If a dose is missed, the official instruction is to skip the missed dose entirely and resume the treatment regimen with the next scheduled daily dose; a double dose must not be taken.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Atorval

Evidence for Managing High Cholesterol (Dyslipidemia)

Research exploring the use of Atorval for high cholesterol relies on Randomized Controlled Trials (RCTs) and comprehensive systematic reviews. These studies were used to understand how changes in blood lipid levels, such as the low-density lipoprotein cholesterol (LDL-C), total cholesterol, and triglycerides, were monitored in the studied populations. The findings describe patterns observed where the lipid biomarkers showed changes in the groups receiving Atorval over defined short-term to intermediate time intervals. The evidence helps contextualize the patterns observed in patients who have elevated blood lipids.

Evidence for Preventing Future Heart and Stroke Events (Primary and Secondary Prevention)

The evidence base for Atorval in prevention settings comes from large-scale, long-term RCTs that specifically monitored the occurrence of hard clinical endpoints. These trials examined outcomes in the context of major cardiovascular events, such as non-fatal heart attacks, strokes, and the need for revascularization procedures. Long-term trials described the frequency of major cardiovascular events in the groups receiving Atorval compared to the control groups. Reports described patterns observed where the event rates monitored in the Atorval-assigned groups varied from those observed in the control groups over the multi-year duration of the trials.

Research Gaps and What Remains Uncertain

While research exists on a wide scale describing the patterns observed with Atorval, several areas remain uncertain. For specific populations, such as those with very low cardiovascular risk or those with isolated triglyceride issues, limited information is available for long-term outcomes because large-scale trials were not primarily designed for these groups. In pediatric populations, the follow-up durations were limited. Additionally, findings describe group patterns, which is a limitation regarding prediction of individual patient outcomes.

Frequently Asked Questions (FAQ)

Common questions about Atorval (FAQ)

Q: What is Atorval used for?

A: Atorval is a medication that belongs to a class of drugs called HMG-CoA reductase inhibitors, or statins. It is indicated for use along with diet to reduce elevated levels of total cholesterol, LDL-C ("bad" cholesterol), and triglycerides in the blood. Its use is associated with a potential reduction in the risk of certain cardiovascular events in specific patient populations.

Q: How does Atorval work?

A: Atorval works by inhibiting the enzyme HMG-CoA reductase in the liver. This enzyme plays a role in the production of cholesterol. By reducing the liver's ability to produce cholesterol, Atorval helps lower the concentrations of cholesterol in the bloodstream.

Q: What are the common side effects of Atorval?

A: Clinical data suggests that common side effects observed with Atorval may include headache, joint pain (arthralgia), nausea, muscle pain (myalgia), and diarrhea. Serious but rare side effects that have been reported include muscle breakdown (rhabdomyolysis) and liver issues. You should discuss all potential side effects and concerns with a healthcare provider.

How should Atorval be stored and disposed of?

Storage and Disposal of Atorvastatin

Atorval (atorvastatin) tablets must be stored at controlled room temperature, typically 20 to 25C (68 to 77F), as defined in official regulatory labeling. The medicine must be protected from environmental factors by keeping it away from excess heat, moisture, and direct light.

Mandatory Storage Conditions

  • Store in the original container, tightly closed.
  • Must be kept from freezing.
  • Keep the product out of the sight and reach of children.

Official Disposal Instructions

Expired or unused tablets should be discarded using a drug take-back program when available. If a take-back program is not accessible, the product should be mixed with an undesirable substance (such as dirt or used coffee grounds) and placed into a sealed container before being thrown into the household trash, in accordance with government guidelines. Do not dispose of the medicine via wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagGreece

flagMalta

Equivalent of Atorval found in:

A-Z Index: